Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Moskowitz

Showing results (271-280 of 298) with videos related to

Pageof 30
Sort By:
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Blood|July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, et al.
The New England Journal of Medicine|November 20, 2013
Mitral-valve repair versus replacement for severe ischemic mitral regurgitationMichael A Acker, Michael K Parides, Louis P Perrault, et al.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin LymphomaAnita Kumar, Carla Casulo, Ranjana H Advani, et al.
The New England Journal of Medicine|November 10, 2015
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral RegurgitationDaniel Goldstein, Alan J Moskowitz, Annetine C Gelijns, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationMohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin LymphomaPallawi Torka, Tatyana Feldman, Kerry J Savage, et al.
The Journal of Thoracic and Cardiovascular Surgery|January 20, 2023
Pacemaker implantation associated with tricuspid repair in the setting of mitral valve surgery: Insights from a Cardiothoracic Surgical Trials Network randomized trialGorav Ailawadi, Pierre Voisine, Samantha Raymond, et al.
Pageof 30

Showing results (271-280 of 298) with videos related to

Sort By:
Pageof 30
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Blood|July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, et al.
The New England Journal of Medicine|November 20, 2013
Mitral-valve repair versus replacement for severe ischemic mitral regurgitationMichael A Acker, Michael K Parides, Louis P Perrault, et al.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin LymphomaAnita Kumar, Carla Casulo, Ranjana H Advani, et al.
The New England Journal of Medicine|November 10, 2015
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral RegurgitationDaniel Goldstein, Alan J Moskowitz, Annetine C Gelijns, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationMohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin LymphomaPallawi Torka, Tatyana Feldman, Kerry J Savage, et al.
The Journal of Thoracic and Cardiovascular Surgery|January 20, 2023
Pacemaker implantation associated with tricuspid repair in the setting of mitral valve surgery: Insights from a Cardiothoracic Surgical Trials Network randomized trialGorav Ailawadi, Pierre Voisine, Samantha Raymond, et al.
Pageof 30